SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

CAVAZZINI, Francesco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.737
EU - Europa 2.338
AS - Asia 1.809
OC - Oceania 7
SA - Sud America 6
Continente sconosciuto - Info sul continente non disponibili 5
AF - Africa 4
Totale 12.906
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.732
CN - Cina 1.049
DE - Germania 542
UA - Ucraina 511
TR - Turchia 467
IT - Italia 410
GB - Regno Unito 264
SE - Svezia 202
SG - Singapore 184
FI - Finlandia 122
FR - Francia 78
PL - Polonia 62
RU - Federazione Russa 56
BE - Belgio 31
CZ - Repubblica Ceca 29
ID - Indonesia 26
VN - Vietnam 22
IN - India 17
HK - Hong Kong 15
JP - Giappone 7
AU - Australia 6
NL - Olanda 6
CA - Canada 5
EU - Europa 5
IE - Irlanda 5
IR - Iran 5
BR - Brasile 4
IL - Israele 4
KR - Corea 4
AT - Austria 2
BG - Bulgaria 2
DK - Danimarca 2
EG - Egitto 2
ES - Italia 2
KZ - Kazakistan 2
PK - Pakistan 2
PT - Portogallo 2
RO - Romania 2
BD - Bangladesh 1
BO - Bolivia 1
CH - Svizzera 1
CO - Colombia 1
DZ - Algeria 1
EE - Estonia 1
GR - Grecia 1
HU - Ungheria 1
LT - Lituania 1
MK - Macedonia 1
MY - Malesia 1
NZ - Nuova Zelanda 1
RS - Serbia 1
RW - Ruanda 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
UZ - Uzbekistan 1
Totale 12.906
Salva come PNG Salva come JPEG
Città #
Woodbridge 1.238
Fairfield 1.181
Houston 814
Chandler 648
Jacksonville 625
Ashburn 540
Ann Arbor 487
Seattle 451
Wilmington 424
Cambridge 379
Beijing 342
Izmir 226
Nanjing 199
Princeton 170
Ferrara 152
New York 122
Boardman 118
San Diego 112
Singapore 109
Shanghai 93
Addison 90
Milan 70
Shenyang 67
Nanchang 63
Warsaw 60
Bremen 45
Hebei 45
Falls Church 33
Redwood City 32
Brussels 31
Changsha 30
Jinan 29
Tianjin 29
Jiaxing 27
London 27
Jakarta 26
Mountain View 23
Brno 22
Dong Ket 22
Dearborn 21
Zhengzhou 21
Los Angeles 19
Norwalk 19
Des Moines 17
San Mateo 15
Hong Kong 14
Kunming 14
Ningbo 14
Orange 13
San Jose 13
Auburn Hills 12
Guangzhou 12
Hefei 12
Leawood 12
Tappahannock 11
Indiana 10
Washington 10
Florence 9
Chicago 8
Fuzhou 8
Taizhou 8
Hangzhou 7
Rome 7
San Francisco 7
Augusta 6
Helsinki 6
Kilburn 6
Philadelphia 6
Redmond 6
Siena 6
Dublin 5
Olomouc 5
Bologna 4
Chengdu 4
Haikou 4
Lanzhou 4
Lappeenranta 4
Minerbe 4
Monmouth Junction 4
Palermo 4
Torino 4
Acton 3
Ahmedabad 3
Changchun 3
Chiswick 3
Edinburgh 3
Hounslow 3
Illasi 3
Kobe 3
Lagopesole 3
Simi Valley 3
Stockholm 3
Tokyo 3
Toronto 3
Verona 3
Al Qahirah al Jadidah 2
Ardabil 2
Atlanta 2
Berlin 2
Boston 2
Totale 9.648
Salva come PNG Salva come JPEG
Nome #
In CLL, comorbidities and the complex karyotype are associated with an inferior outcome independently of CLL-IPI 179
Diagnostic work-up for clinical and prognostic assessment of acute leukaemia 154
Involvement of the P2X7-NLRP3 axis in leukemic cell proliferation and death 154
Clonal evolution including 14q32/IGH translocations in chronic lymphocytic leukemia: analysis of clinicobiologic correlations in 105 patients 134
Incidence and significance of cryptic chromosome aberrations detected by fluorescence in situ hybridization in acute myeloid leukemia with normal karyotype 132
A highly sensitive and specific fluorescence in situ hybridization (FISH) approach for the detection of t(9;11)(p22-23;q23) in acute myeloid leukemia. 129
Employment of Oligodeoxynucleotide plus Interleukin-2 Improves Cytogenetic Analysis in SplenicMarginal Zone Lymphoma 129
Acute Human Herpesvirus-6A infection of human mesothelial cells modulates HLA molecules 128
Secondary chromosome changes in mantle cell lymphoma: cytogenetic and fluorescence in situ hybridization studies. 127
Identifying High-Risk Chronic Lymphocytic Leukemia: A Pathogenesis-Oriented Appraisal of Prognostic and Predictive Factors in Patients Treated with Chemotherapy with or without Immunotherapy 126
null 124
Genetic subclonal complexity and miR125a-5p down-regulation identify a subset of patients with inferior outcome in low-risk CLL patients 123
Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia: Clinical and biologic correlations. 121
Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: Clinical and biological correlations 121
CYTOGENETIC ABERRATIONS IN THE CD38 POSITIVE FRACTION OF CD38 NEGATIVE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS: A MARKER OF AGGRESSIVENESS? 119
Clinical importance of interphase cytogenetics detecting occult chromosome lesions in myelodysplastic syndromes with normal karyotype 119
Soluble urokinase-type Plasminogen Activator Receptor (suPAR) as an independent factor predicting worse prognosis and extra bone marrow involvement in multiple myeloma patients 118
In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biological characteristics 118
Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib 116
An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractoriness 115
An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractoriness 115
Hepatosplenic T-cell lymphoma (HSTCL). 112
Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia: Clinical and biologic correlations 112
Chronic lymphocytic leukemia with 6q- shows distinct hematological features and intermediate prognosis 111
Angiogenesis in multiple myeloma: correlation between in vitro endothelial colonies growth (CFU-En) and clinical-biological features. 110
Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors 110
TYROSINE KINASE INHIBITORS DISCONTINUATION IN CHRONIC MYELOID LEUKEMIA: A RETROSPECTIVE ANALYSIS OF 208 ITALIAN PATIENTS 110
A novel recurrent translocation t(11;14)(p11;q32) in splenic marginal zone B cell lymphoma 110
Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL) 109
Myelofibrosis with Myeloid Metaplasia (MMM)/Idiopathic myelofibrosis/Agnogenic myeloid metaplasia 108
Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients 107
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib 107
Trisomy 8 in PDGFRB-negative cells in a patient with imatinib-sensitive chronic myelomonocytic leukemia and t(5;16)(q33;p13) PDGFRB-NDE1 fusion 106
Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib 106
Proliferation centers in chronic lymphocytic leukemia: correlation with cytogenetic and clinicobiological features in consecutive patients analyzed on tissue microarrays 106
Erratum to: Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations (J Hematol Oncol. (2016) 9 (88) DOI:10.1186/s13045-016-0320-z) 106
Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival 106
Age Influences Initial Dose and Compliance to Imatinib In Chronic Myeloid Leukemia Elederly Patients but Concomitant Comorbidities Appear to Influence Overall and Event-Free Survival 105
Increased serum levels of matrix metalloproteinase-9 predict clinical outcome of patients with early B-cell chronic lymphocytic leukaemia. 104
MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia 104
PAX5/IGH rearrangement is a recurrent finding in a subset of aggressive B-NHL with complex chromosomal rearrangements 103
HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN A PATIENT WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITH IBRUTINIB 101
A highly sensitive and specific fluorescence in situ hybridization (FISH) approach for the detection of t(9;11)(p22-23;q23) in acute myeloid leukemia. 100
CLINICAL AND BIOLOGICAL CHARACTERIZATION OF CIRCULATING ENDOTHELIAL CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA 100
Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients. 100
null 100
Alterations of loci encoding PU.1, BOB1, and OCT2 transcription regulators do not correlate with their suppressed expression in Hodgkin lymphoma. 99
Intestinal T-cell lymphoma 99
THE EUTOS LONG-TERM SURVIVAL SCORE IS PREDICTIVE FOR RESPONSE AND OUTCOME IN CML PATIENTS TREATED FRONTLINE WITH NILOTINIB-BASED REGIMENS 99
“Hemophagocytic Lymphohistiocytosis after EBV reactivation and ibrutinib treatment in relapsed/refractory Chronic Lymphocytic Leukemia” 98
Detection of inherited chromosomally integrated HHV-6 (ciHHV-6) in a marker chromosome 98
The Dose and the duration of frontline therapy with Imatinib does not affect response to Dasatinib in Imatinib-Resistant or -intolerant patients with chronic myeloid leukemia (CML). Results from a real Life-Based Italian Multicenter retrospective study on 124 Patients. 97
Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia 97
Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis. 97
Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) 96
Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia 95
B-Cell chronic lymphocytic leukemia (B-CLL) with 14q32 translocations: haematological features and clinical outcome. 94
Biological significance and prognostic/predictive impact of complex karyotype in chronic lymphocytic leukemia 94
Four novel non-random chromosome rearrangements in B-cell chronic lymphocytic leukaemia: 6p24-25 and 12p12-13 translocations, 4q21 anomalies and monosomy 21 93
Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia with "normal" FISH: Correlations with clinicobiologic parameters 93
Circulating endothelial cells in patients with chronic lymphocytic leukemia: clinical-prognostic and biological significance 92
Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia 91
Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leukemia. 90
VERY ELDERLY CP-CML PATIENTS TREATED WITH IMATINIB FRONTLINE: HAVE CONCOMITANT THERAPIES AN IMPACT ON OUTCOME AND TOXICITY? 90
Molecular cytogenetic characterization of marginal zone B-cell lymphoma: correlation with clinicopathologic findings in 14 cases 89
EFFICACY AND SAFETY PROFILE OF DASATINIB IN A SUBSET OF VERY ELDERLY PATIENS WITH CHRONIC MYELOID LEUKEMIA (CML) RESISTANT/INTOLERANT TO IMATINIB 89
APPLICATION of EUTOS SCORE IN CHRONIC Myeloid LEUKEMIA AFFECTING VERY Elderly (>75 years) PATIENTS 89
Identifying High-Risk Chronic Lymphocytic Leukemia: A Reappraisal of the Impact of Prognostic and Predictive Factors 88
null 88
Expression of the immunoglobulin superfamily cell membrane adhesion molecule Cd146 in acute leukemia 88
Abnormalities of chromosomes 1p34-36, 4p16, 4q35, 9q11-32 and +7 represent novel recurrent cytogenetic rearrangements in chronic lymphocytic leukemia 88
Chromosome Aberrations by Conventional Karyotyping in Chronic Lymphocytic Leukemia Carrying No Aberration by Fluorescence in Situ Hybridization: Correlation with Prognostic Parameters and Clinical Features 87
Alterazioni cromosomiche in cellule staminali emopoietiche indotte da esposizioni ambientali o professionali. 86
Hemophagocytic Lymphohistiocytosis in a Patient with Relapsed Chronic Lymphocytic Leukemia Treated with Ibrutinib 86
Multilineage involvement in the 5q- syndrome: a fluorescent in situ hybridization study on bone marrow smears. 85
Imatinib In Very Elderly CML Patients: What Can We Achieve? 85
IMPACT OF BCR-ABL MUTATIONS ON RESPONSE TO DASATINIB IN ELDERLY CHRONIC MYELOID LEUKEMIA PATIENTS RESISTANT TO IMATINIB 85
CHROMOSOME ABNORMALITIES ADDITIONAL TO THE PHILADELPHIA CHROMOSOME AT THE DIAGNOSIS OF CHRONIC MYELOID LEUKEMIA. PATHOGENETIC AND PROGNOSTIC IMPLICATIONS. 85
Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome 85
Modern treatment in chronic lymphocytic leukemia: impact on survival and efficacy in high-risk subgroups. 85
null 85
Clinicobiologic importance of cytogenetic lesions in chronic lymphocytic leukemia 84
Essential Thrombocythemia (ET) 84
Cytogenetic and molecular cytogenetic characterization of 6 new cases of idiopathic hypereosinophilic syndrome 81
Alternating Nilotinib 400 mg twice daily and Imatinib 400 mg once daily as Frontline Treatment of Ph+ Chronic Myeloid Leukemia. A Phase 2 Multicentric Study of the GIMEMA CML Working Party 81
Efficacy and Safety of Ruxolitinib in Elderly Patients (> 75 years) with Myelofibrosis 81
Outcome of Patients with CML Treated with Dasatinib or Nilotinib after Failure of Second Prior TKIs. 80
Imatinib in Very Elderly (> 75 years) CML Patients: Are Low-Doses (<400 mg daily) Enough? 80
The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia 79
null 78
null 78
TREATMENT, RESPONSE, AND OUTCOME IN UNSELECTED ELDERLY PATIENTS WITH NEWLY DIAGNOSED, CHRONIC PHASE (CP), PHILADELPHIA CHROMOSOME-POSITIVE (PH plus ) CHRONIC MYELOID LEUKEMIA 78
A Population-Based Study of Chronic Myeloid Leukemia Treated with Imatinib in First Line 78
Predictors for Response to Ruxolitinib in Real-Life: An Observational Independent Study on 408 Patients with Myelofibrosis 77
Clonal evolution in chronic lymphocytic leukemia: analysis of clinicobiologic correlations in 105 patients 75
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 74
Significato dell'analisi citogenetica e citogenetico-molecolare nella diagnosi e nella prognosi delle neoplasie ematologiche. Cytogenetics and molecular cytogenetics in diagnosis and prognosis of haematological malignancies 73
LONG-TERM OUTCOME TO FIRST-LINE IMATINIB ACCORDING TO 2013 EUROPEAN LEUKEMIANET RESPONSE CRITERIA: A GIMEMA CML WP ANALYSIS 73
Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: A retrospective study 71
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients 70
Totale 10.014
Salva come PNG Salva come JPEG
Categoria #
all - tutte 57.074
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 2.878
Totale 59.952
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.894 438 72 79 420 209 357 277 292 259 299 135 57
2020/20212.170 141 149 91 207 121 200 71 241 41 322 396 190
2021/20221.647 129 188 54 59 84 112 93 97 44 137 163 487
2022/20231.579 180 88 64 182 259 209 74 167 210 7 89 50
2023/2024780 79 91 37 18 38 143 42 54 24 16 26 212
2024/202574 74 0 0 0 0 0 0 0 0 0 0 0
Totale 13.183